Seer, Inc. received two unsolicited acquisition proposals, one for $2.55 and another for $2.45 per share.
Quiver AI Summary
Seer, Inc. announced that it received two unsolicited, non-binding acquisition proposals for its Class A common stock. The first was from the Radoff-JEC Group, offering $2.55 per share plus a contingent value right, while the second, from Seer's Chair and CEO Omid Farokhzad, proposed $2.45 per share along with two contingent value rights. Seer's Board has a Special Committee that will review both offers and determine the best course of action for the company and its shareholders, with no immediate stockholder action required. Seer, known for its innovative proteomic insights, emphasizes that its products are intended for research use only and not for diagnostics.
Potential Positives
- Seer has received multiple unsolicited acquisition proposals, indicating that the company is regarded as a valuable asset in the market.
- The presence of two competing offers may drive an increase in shareholder value, as the Special Committee evaluates both proposals.
- The proposals suggest interest from reputable figures in the industry, potentially enhancing Seer’s credibility and reputation.
Potential Negatives
- Seer's current acquisition proposals from two parties highlight potential instability in the company's leadership and ownership structure, which could raise concerns among investors about the company's future direction.
- The offers being below the company's perceived value may indicate a lack of confidence in Seer's operational performance or growth prospects.
- The solicitation of unsolicited acquisition proposals may attract unwanted attention from other potential acquirers or disrupt ongoing business operations, creating uncertainty within the company.
FAQ
What acquisition proposals has Seer, Inc. received?
Seer received proposals from both the Radoff-JEC Group at $2.55 per share and Dr. Omid Farokhzad at $2.45 per share.
Who is reviewing the acquisition proposals at Seer?
The Special Committee of Seer’s Board of Directors is reviewing both acquisition proposals and considering all options.
What is the current status of Seer's stockholders regarding the proposals?
No stockholder action is required at this time regarding the acquisition proposals.
What products does Seer, Inc. offer?
Seer offers the Proteograph® Product Suite for deep proteomics research, designed for research use only, not diagnostics.
Where can I find more information about Seer, Inc.?
You can visit Seer’s website at www.seer.bio or email them at [email protected] for more information.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SEER Insider Trading Activity
$SEER insiders have traded $SEER stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $SEER stock by insiders over the last 6 months:
- OMID FAROKHZAD (CEO AND CHAIR) sold 24,385 shares for an estimated $48,645
- DAVID R. HORN (PRESIDENT & CFO) has made 0 purchases and 2 sales selling 15,046 shares for an estimated $27,798.
- DIPCHAND NISHAR sold 10,660 shares for an estimated $23,265
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SEER Hedge Fund Activity
We have seen 15 institutional investors add shares of $SEER stock to their portfolio, and 33 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIREN, L.L.C. removed 1,541,327 shares (-38.5%) from their portfolio in Q1 2026, for an estimated $2,589,429
- FMR LLC removed 703,242 shares (-99.9%) from their portfolio in Q1 2026, for an estimated $1,181,446
- TWO SIGMA INVESTMENTS, LP added 258,951 shares (+102.5%) to their portfolio in Q1 2026, for an estimated $435,037
- T3 COMPANIES, LLC removed 170,962 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $283,796
- RANGELEY CAPITAL, LLC added 164,302 shares (+821.5%) to their portfolio in Q1 2026, for an estimated $276,027
- BRIDGEWAY CAPITAL MANAGEMENT, LLC removed 150,000 shares (-24.6%) from their portfolio in Q1 2026, for an estimated $252,000
- MILLENNIUM MANAGEMENT LLC removed 116,497 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $195,714
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
REDWOOD CITY, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today confirmed that on July 28, 2026, it received a further revised, unsolicited, non-binding acquisition proposal from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”) to acquire all of the outstanding shares of Seer’s Class A common stock for $2.55 per share in cash plus a contingent value right.
On July 29, 2026, Seer received a revised, unsolicited, non-binding acquisition proposal from Omid Farokhzad, M.D., Seer’s Chair and Chief Executive Officer, to acquire all of the outstanding shares of Seer’s Class A common stock for $2.45 per share in cash plus two separate contingent value rights. The full text of the letter received from Dr. Farokhzad outlining his revised proposal will be included in a Form 8-K filing made by Seer.
The previously constituted Special Committee of Seer’s Board of Directors, in consultation with its advisors, will carefully review and consider both proposals, as well as other alternatives available to Seer, and determine the course of action that it believes is in the best interests of Seer and all Seer stockholders.
No stockholder action is required at this time.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer's Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer's products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at [email protected] .
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this communication. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding the actions of the Special Committee. These and other risks are described more fully in Seer’s filings with the SEC and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
[email protected]
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
